A Phase II Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Approximately 48 month from the date of IRB approval
Patients enrolled in this study targets approximately 314 people. Completion of patient
enrollment is expected to take approximately 24 month, approximately 24 month follow-up
period is expected to be needed
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
24month progression free survival
24 months
Yes
Korea: Food and Drug Administration
KGOG3017
NCT01570582
March 2010
March 2014
Name | Location |
---|